[The hemoprotective effect of Dicarbamin in ovarian cancer patients receiving chemotherapy].
The effect of dicarbamin on the hemopoetic cells of the bone marrow of ovarian cancer patients receiving myelosuppressive combination chemotherapy (cyclophosphamide + carboplatin) is discussed.
Raĭkhlin
N T
NT
N.N. Blokhin Center for Oncology Research, Russian Academy of Medical Sciences, Moscow.
Gorbunova
V A
VA
Treshchalina
E M
EM
Bychkov
M B
MB
Smirnova
E A
EA
Mindra
N V
NV
Topchieva
S V
SV
Zubrikhina
G N
GN
Nebol'sin
V E
VE
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000648:ultrastructure; D002208:Caproates; D016190:Carboplatin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced / Q000517:prevention & control*; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D002208:Caproates; D007093:Imidazoles; C539419:pentanedioic acid imidazolyl ethanamide; D003520:Cyclophosphamide; D016190:Carboplatin